

EXHIBIT A



DOCKETED <input checked="" type="checkbox"/>	DATED <input checked="" type="checkbox"/>	CHECKED <input checked="" type="checkbox"/>
UNITED STATES PATENT AND TRADEMARK OFFICE		
Action Required: <u>Issue Fee Due 08.21.07: small</u>		
Entity <u>6-K</u> : <u>check PTA - sub says o.k.</u> <u>file</u>		
Publ. Info.		
Appl./Grant Info.		
Due Date: <u>08.21.07</u>		
Completed: <u>NOTICE OF ALLOWANCE AND FEE(S) DUE</u>		
Docketed By: <u>FVS</u>		
MDC <input type="checkbox"/>	CLDR <input type="checkbox"/>	OLD <input type="checkbox"/> S/R <input type="checkbox"/>

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

52101 7590 05/21/2007
PEREGRINE PHARMACEUTICALS, INC.
5353 WEST ALABAMA
SUITE 306
HOUSTON, TX 77056

PEREGRINE
IP DIVISION
RECEIVED

MAY 23 2007

EXAMINER	
GODDARD, LAURA B	
ART UNIT	PAPER NUMBER

1642
DATE MAILED: 05/21/2007

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,118	08/15/2003	Philip E. Thorpe	4001.003085/UTSD:0893-	1453
TITLE OF INVENTION: SELECTED ANTIBODY CDRS FOR BINDING TO AMINOPHOSPHOLIPIDS				

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES <input checked="" type="checkbox"/>	\$700	\$300	\$0	\$1000	08/21/2007

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. ROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. HIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

If the status is the same, pay the TOTAL FEE(S) DUE shown above.

If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (PTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a separate paper as an equivalent of Part B.

All communications regarding this application must give the application number. Please direct all communications prior to issuance to the Commissioner of Patents and Trademarks. Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issued on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and file this form, together with applicable fee(s), to: **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated on the front of the form or directed below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

52101 7590 05/21/2007
PEREGRINE PHARMACEUTICALS, INC.
5353 WEST ALABAMA
SUITE 306
HOUSTON, TX 77056

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,118	08/15/2003	Philip E. Thorpe	4001.003085/UTSD:0893-	1453

TITLE OF INVENTION: SELECTED ANTIBODY CDRS FOR BINDING TO AMINOPHOSPHOLIPIDS

-4

1453

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$0	\$1000	08/21/2007

EXAMINER	ART UNIT	CLASS-SUBCLASS
GODDARD, LAURA B	1642	530-387100

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list
(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
(A) NAME OF ASSIGNEE:
(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

Change in Entity Status (from status indicated above)

☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete a form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

JUL 16 2007



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,118	08/15/2003	Philip E. Thorpe	4001.003085/UTSD:0893-	1453
52101	7590	05/21/2007	EXAMINER	
PEREGRINE PHARMACEUTICALS, INC. 5353 WEST ALABAMA SUITE 306 HOUSTON, TX 77056			GODDARD, LAURA B	
			ART UNIT	PAPER NUMBER

1642
DATE MAILED: 05/21/2007


Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 394 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 394 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.



Notice of Allowability

Application No.

10/642,118

Examiner

Laura B. Goddard, Ph.D.

Applicant(s)

THORPE ET AL.

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 3/15/2007.

2. ☒ The allowed claim(s) is/are 1-21.

3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some* c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.

(a) ☐ Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached

1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.

(b) ☐ Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)

2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

3. ☐ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____

4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material

5. ☐ Notice of Informal Patent Application

6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____

7. ☐ Examiner's Amendment/Comment

8. ☐ Examiner's Statement of Reasons for Allowance

9. ☐ Other _____

Sharon A. Foley
SHARON FOLEY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600



CLAIMS TO ISSUE
SERIAL NO. 10/642,118 (4001.003085)

1. (Previously Presented) A purified antibody that binds to phosphatidylserine and comprises at least one variable region that comprises three CDRs, wherein said variable region is:
 - (a) a heavy chain variable region that comprises a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO:10, a VH CDR2 that has the amino acid sequence of SEQ ID NO:11 and a VH CDR3 that has the amino acid sequence of SEQ ID NO:12; or
 - (b) a light chain variable region that comprises a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO:13, a VL CDR2 that has the amino acid sequence of SEQ ID NO:14 and a VL CDR3 that has the amino acid sequence of SEQ ID NO:15.
2. (Previously Presented) The antibody of claim 1, wherein said antibody comprises said heavy chain variable region.
3. (Previously Presented) The antibody of claim 1, wherein said antibody comprises said light chain variable region.
4. (Previously Presented) The antibody of claim 1, wherein said antibody comprises said heavy chain variable region and said light chain variable region.
5. (Previously Presented) The antibody of claim 1, wherein said antibody binds to phosphatidylserine in combination with a protein cofactor.
6. (Previously Presented) The antibody of claim 1, wherein said antibody binds to phosphatidylserine in an ELISA that comprises:
 - (a) adding phosphatidylserine to a solid support;
 - (b) blocking with a blocking buffer comprising 10% serum;
 - (c) adding a primary antibody diluted in said blocking buffer, wherein said primary antibody is said antibody or antigen-binding fragment thereof, that binds to phosphatidylserine; and

- (d) detecting bound primary antibody using a secondary antibody that binds to said primary antibody.
7. (Previously Presented) The antibody of claim 6, wherein said blocking buffer comprises 10% bovine serum.
8. (Previously Presented) The antibody of claim 1, wherein said heavy chain variable region has the amino acid sequence of SEQ ID NO:2.
9. (Previously Presented) The antibody of claim 1, wherein said light chain variable region has the amino acid sequence of SEQ ID NO:4.
10. (Previously Presented) The antibody of claim 1, wherein said antibody comprises a heavy chain variable region that has the amino acid sequence of SEQ ID NO:2 and a light chain variable region that has the amino acid sequence of SEQ ID NO:4.
11. (Previously Presented) The antibody of claim 1, wherein said variable region has a human framework region.
12. (Previously Presented) The antibody of claim 11, wherein said region has a human IgG₁ framework region.
13. (Original) The antibody of claim 1, wherein said antibody comprises a human constant domain.
14. (Previously Presented) The antibody of claim 1, wherein said antibody comprises a variable region that has a human framework region and a human constant domain.
15. (Previously Presented) The antibody of claim 1, wherein said antibody has substantially the same phospholipid binding profile as the monoclonal antibody 3G4 (ATCC PTA 4545); wherein the phospholipid binding profile of the monoclonal antibody 3G4 (ATCC PTA 4545), as determined by relative strength of reactivity on an ELISA, is PS=PA=PI=PG=CL>>PE, wherein > indicates at least 2-fold difference in phospholipid binding and >> indicates at least 10-fold difference in phospholipid binding, each at identical antibody concentrations.

16. (Previously Presented) The antibody of claim 1, wherein said antibody has an affinity for phosphatidylserine of at least equal to the affinity of the monoclonal antibody 3G4 (ATCC PTA 4545) for phosphatidylserine; wherein the affinity of the monoclonal antibody 3G4 (ATCC PTA 4545) for phosphatidylserine, as determined in an ELISA, has an EC_{50} value of 0.040 $\mu\text{g/ml}$.

17. (Original) The antibody of claim 1, wherein said antibody is comprised in a pharmaceutically acceptable composition.

18. (Previously Presented) A composition comprising a biologically effective amount of the antibody of claim 1.

19. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody of claim 1.

20. (Previously Presented) The antibody of claim 15, wherein said antibody binds to phosphatidylserine in an ELISA that comprises:

- (a) adding phosphatidylserine to a solid support;
- (b) blocking with a blocking buffer comprising 10% serum;
- (c) adding a primary antibody diluted in said blocking buffer, wherein said primary antibody is said antibody or antigen-binding fragment thereof, that binds to phosphatidylserine; and
- (d) detecting bound primary antibody using a secondary antibody that binds to said primary antibody.

21. (Previously Presented) The antibody of claim 20, wherein said blocking buffer comprises 10% bovine serum.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/642,118	07/24/2007	7247303	4001.003085/UTSD:0893- -4	1453

52101 7590 07/04/2007
PEREGRINE PHARMACEUTICALS, INC.
5353 WEST ALABAMA
SUITE 306
HOUSTON, TX 77056

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 394 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Philip E. Thorpe, Dallas, TX;
Sophia Ran, Riverton, IL;